Aktie 003020 HEFEI LIFEON PHARMACEUTICAL CO., LTD.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen Hefei Lifeon Pharmaceutical Co., Ltd.

Aktien

003020

CNE100004BD9

003020

Schlusskurs Shenzhen S.E.
Andere Börsenplätze
 00:00:00 24.05.2024 		% 5 Tage % 1. Jan.
25,18 CNY +1,70 % Intraday Chart für Hefei Lifeon Pharmaceutical Co., Ltd. +6,24 % -10,55 %
29.04. Hefei Lifeon Pharmaceutical Co., Ltd. meldet Ergebnis für das erste Quartal bis zum 31. März 2024 CI
22.04. Hefei Lifeon Pharmaceutical Co., Ltd. meldet Ergebnis für das am 31. Dezember 2023 endende Geschäftsjahr CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
Lifeon Pharmaceutical's Unit Gets Marketing Authorization for Loxoprofen Sodium Oral Solution
Hefei Lifeon Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
Hefei Lifeon Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
Lifeon Pharma’s Diabetes Drugs Pass China Consistency Evaluation
Certain A Shares of Hefei Lifeon Pharmaceutical Co., Ltd. are subject to a Lock-Up Agreement Ending on 15-DEC-2023.
Lifeon Pharmaceutical Gets Chinese Drug Regulator's Nod to Market Doxazosin Mesylate
Hefei Lifeon Pharmaceutical Co., Ltd. Approves Election of Shi Jing as an Independent Director
Hefei Lifeon Pharmaceutical Co., Ltd., Hefei Xinchen Enterprise Management Consulting Co., Ltd., Li Chao and Deng Xiaojuan agreed to acquire Hefei Noratech Pharmaceuticals Co., Ltd. from Roaring Success Ltd and Hefei Xinchen Enterprise Management Consulting Co., Ltd. for CNY 72 million.
Hefei Lifeon Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023
Hefei Lifeon Pharmaceutical Co., Ltd.(XSEC:003020) added to S&P Global BMI Index
Hefei Lifeon Pharmaceutical Co., Ltd. signed equity transfer agreement to acquire 51% stake in Anhui Joyfar Pharmaceutical Co. Ltd. from Beijing Huixu Jintong Investment Center (Limited Partnership), Beijing Huixu Jintai Investment Center (Limited Partnership), Gong Tonglin, Shen Jun, Zhao Shoutian and Ouyang Hanlin for approximately CNY 220 million.
Hefei Lifeon Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023
Hefei Lifeon Pharmaceutical Co., Ltd. Declares Cash Dividend on A Shares for 2022, Payable on May 24, 2023
Hefei Lifeon Pharmaceutical Co., Ltd. Approves Cash Dividend for the Year 2023
Hefei Lifeon Pharmaceutical Co., Ltd. Proposes Final Dividend for 2022
Hefei Lifeon Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023
Hefei Lifeon Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022
Hefei Lifeon Pharma’s Blood Pressure Drug Joins Bid For Inclusion in China’s Drug Procurement Program
Worldunion Group CFO Resigns; Successor Named
Anhui Lifeon Pharmaceutical Co., Ltd. announced that it expects to receive CNY 113 million in funding from Hefei Lifeon Pharmaceutical Co., Ltd.
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. 003020 Aktie
  4. Nachrichten Hefei Lifeon Pharmaceutical Co., Ltd.
  5. Andere Sprachen